Cargando…

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

OBJECTIVE: Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder characterised by fibrosis and microvascular obliteration of the skin and internal organs. Organ involvement mostly manifests after a variable period of the onset of Raynaud's phenomenon (RP). We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaeger, Veronika K., Wirz, Elina G., Allanore, Yannick, Rossbach, Philipp, Riemekasten, Gabriela, Hachulla, Eric, Distler, Oliver, Airò, Paolo, Carreira, Patricia E., Balbir Gurman, Alexandra, Tikly, Mohammed, Vettori, Serena, Damjanov, Nemanja, Müller-Ladner, Ulf, Distler, Jörg H. W., Li, Mangtao, Walker, Ulrich A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051961/ https://www.ncbi.nlm.nih.gov/pubmed/27706206 http://dx.doi.org/10.1371/journal.pone.0163894

Ejemplares similares

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population
por: Hachulla, Eric, et al.
Publicado: (2015)

Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database
por: Allanore, Yannick, et al.
Publicado: (2020)

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
por: Bütikofer, Lukas, et al.
Publicado: (2020)

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
por: Blagojevic, J., et al.
Publicado: (2019)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Role of MicroRNAs in Fibrosis
por: Vettori, Serena, et al.
Publicado: (2012)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis
por: Allanore, Yannick, et al.
Publicado: (2011)

A broad look into the future of systemic sclerosis
por: Riemekasten, Gabriela, et al.
Publicado: (2022)

Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China
por: Hu, Shasha, et al.
Publicado: (2018)

Volumetric Cone Beam Computed Tomography for the Assessment of Oral Manifestations in Systemic Sclerosis: Data from an EUSTAR Cohort
por: Iordache, Cristina, et al.
Publicado: (2019)

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts
por: Müller-Ladner, Ulf, et al.
Publicado: (2007)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2015)

Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2023)

Editorial: Precision Medicine in Chronic Inflammation
por: Distler, Oliver, et al.
Publicado: (2021)

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
por: Bruni, Cosimo, et al.
Publicado: (2022)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse
por: Ledein, Laetitia, et al.
Publicado: (2020)

Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group
por: Foocharoen, Chingching, et al.
Publicado: (2012)

Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases
por: Micheroli, Raphael, et al.
Publicado: (2022)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
por: Codreanu, Catalin, et al.
Publicado: (2015)

Intra-articular autologous conditioned serum and triamcinolone injections in patients with knee osteoarthritis: a controlled, randomized, double-blind study
por: Damjanov, Nemanja, et al.
Publicado: (2023)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
por: Hesselstrand, Roger, et al.
Publicado: (2021)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?
por: Vanhaecke, Amber, et al.
Publicado: (2022)

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study
por: Peytrignet, Sébastien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ufa1hioamb2n09vaatfufit7s2